Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
TSHA
Strong SellSinkerTaysha Gene Therapies, Inc. · Healthcare · United States · $1.9B · Avg Vol: $13M/d
COMPANY DESCRIPTION
Taysha Gene Therapies, Inc. is a clinical-stage gene therapy company focused on developing therapies for monogenic central nervous system (CNS) diseases. The company utilizes a robust adeno-associated virus (AAV) gene therapy platform to address a range of neurological disorders with high unmet medical needs. Taysha operates as a specialized player in the burgeoning gene therapy sector, aiming to deliver potentially curative treatments for severe inherited brain disorders.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5M | 15.5M | 8.3M | 9.8M | 57.5% | 5.5M | 1.8M | 19.7M | 41.8% |
| EPS | -0.83 | -0.96 | -0.36 | -0.34 | — | -0.41 | -0.47 | -0.46 | — |
| Shares | 287.4M | 187.0M | 204.9M | 285.1M | -0.8% | 325.8M | — | — | — |
| Debt | 59.9M | 61.1M | 63.2M | 70.1M | 5.4% | 56.7M | — | — | — |
| Equity | 0.9M | 74.9M | 71.5M | 246.9M | 538.4% | — | — | — | — |
| Op CF | -88.4M | -73.0M | -81.2M | -93.1M | — | -132.2M | — | — | — |
| Inv CF | -24.9M | -7.4M | -0.4M | -0.6M | — | — | — | — | — |
| Fin CF | 52.1M | 136.4M | 76.7M | 274.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TSHA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc.(you) | $1.9B | 14 | Strong Sell |
| INBX | Inhibrx Biosciences, Inc. | $1.8B | 13 | Strong Sell |
| ZBIO | Zenas BioPharma, Inc. | $2.0B | 15 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 12 | Strong Sell |
| STOK | Stoke Therapeutics, Inc. | $2.0B | 13 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| MLYS | Mineralys Therapeutics, Inc. | $2.3B | 14 | Strong Sell |
| BRVE | Braveheart Bio, Inc. | $1.9B | 11 | Strong Sell |
| KLRA | Kailera Therapeutics, Inc. | $2.1B | 11 | Strong Sell |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 16 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.1%